Endocrine Abstracts

Introduction: The interaction between bone and energy metabolism may be enhanced in high demanding physical activities. We hypothesize that genetic background may modulate the exercise-associated bone and energy responses of athletes participating of a mountain cycling ultramarathon.Methods: Fifty-five non-professional athletes (mean age 44.8±7.1 years) participating in a 9-day mountain cycling ultramarathon (TransPortugal) were evaluated. Before an...

Objectives: To study the association of functional polymorphisms at DHFR, CBS and MTHFR genes with bone mineral density (BMD) and metabolic parameters of bone remodeling.Materials and methods: BMD (g/cm2) was measured by DEXA in 391 subjects: 174 with normal BMD (137F 37M; age=48.79±12.99 years; BMI=29.61±5.22 kg/m2), 62 with osteopenia (48F 14M; age=56.06±12.96 years; BMI=27.64±4.94 kg/m2) and 154 with osteoporosis (119F, 35M; age=64...

Introduction: Acromegaly is a rare disease with significant morbidity and mortality. Surgical treatment is the first line treatment for these patients, with remission rates of >85% for microadenomas and 40–50% for macroadenomas.Objectives: Our objective was to characterize patients with acromegaly followed in our department and evaluate remission status after surgery. We also aimed to determine remission related factors.Me...

Introduction: Differentiated thyroid carcinoma is usually associated with a good prognosis. However, some of these tumors (5%) are radioiodine refractory and have different progression, associated with poor prognosis. In these situations, some tyrosine kinase inhibitors (TKI) can be used. We present a clinical case showing the difficulties in the follow-up and treatment of these patients.Clinical case: A 60 years old woman, with a “multicentric papi...

Background: A systematic literature review (SLR) was conducted to assess the use of independent injections (self/partner/home-administered) as an alternative to healthcare-setting injections for chronic diseases. The primary objective was to identify studies reporting on independent injection of somatostatin analogues (SSAs). Comparative evidence on independent injection of other medications was examined as a secondary objective.Methods: MEDLINE/Embase/t...

Background: Acromegaly is a rare disorder characterized by excess growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Extended dosing intervals (EDIs) of pharmacological treatments may reduce patient burden and costs compared with standard dosing. This systematic literature review (SLR) investigated treatment of acromegaly at EDIs.Methods: MEDLINE/Embase/the Cochrane Library (2001–June 2021) and key congresses (2018–2021) were searche...

Background: We recently have shown a close association of high concentrations of soluble alpha klotho (sαKL) to disease activity in acromegaly. Small pilot studies suggested that sαKL concentrations might be reduced in GH deficiency (GHD) and increase after recombinant human GH (rhGH) therapy. Our aim was to evaluate the potential of sαKL as a biomarker in GHD.Methods: We evaluated sαKL in comparison to the classical biomarkers GH, IG...

Background: Medical treatment for acromegaly (characterized by excess growth hormone [GH] production) includes somatostatin receptor ligands (SRLs), dopamine agonists (DAs), and GH receptor antagonists (GHRAs). However, recent real-world United States (US) treatment evaluations are few. We present treatment patterns for patients receiving medications for acromegaly (1/1/2010–31/7/2022).Methods: De-identified data were extracted from MarketScan&...

Pituitary carcinomas are rare and represent a challenge in clinical practice. Most secondary tumour localizations are intracranial and spinal, followed by liver, cervical lymph node, bone and, rarely, lung. PC frequently exhibit resistance to most usual therapies and the mean survival time is usually <4 years once metastases have been identified. Ectopic ACTH Syndrome is, in up to 50% cases, caused by lung tumours including carcinoids or Small Cell Lung Carcinomas (SCLC). ...

Introduction: The anatomical and physiological changes induced by bariatric surgery (BS) can significantly impact the absorption and pharmacokinetics of orally administered medication. In particular, levothyroxine (LT4) dosage, given its dependence on patient’s weight and gastric pH for optimal absorption, is expected to change following BS. However, the literature is not unanimous and there is a void of longer-term studies. We aimed to compare LT4 dosage 4 years followin...